Press Office

Commenting on today’s news that Academic Health Science Networks (AHSNs) are to be established across the NHS in England, Stephen Whitehead, Chief Executive of the ABPI, said: "I am delighted that the new AHSNs, which will help spread innovation throughout the NHS, have today been confirmed."Read more

The ABPI is delighted to announce that it will now represent the vaccine industry to Government and healthcare stakeholders.Read more

Commenting on the final advice from the European Medicines Agency's (EMA) clinical trial advisory groups, Stephen Whitehead, Chief Executive of the ABPI, said: “I am pleased that the EMA is making good progress on designing its policy on access to clinical trial information and the advisory groups have now published their findings."Read more

Responding to news from the European General Court on 30 April 2013, Stephen Whitehead, Chief Executive of the ABPI, said: “We are committed to the increased transparency of clinical trial information as a means to further medical research."Read more

In response to today's article in the Independent on medicines pricing, the ABPI has issued the following statement. Read more

Read our response to the Financial Times leader 'Healing the UK pharma industry' published on Monday 22 April 2013. Read more

The NHS, under pressure to make savings, has resorted to slashing the budget on new medicines as a short term measure to meet spending targets. Cutting down on the newest medicines is one of a number of crude ways in which savings have been achieved to date but there is increasing fear that it is hampering the treatment of people in the NHS.Read more

The pharmaceutical industry takes a major step this week in its on-going transparency drive by beginning to publish aggregate totals of payments made last year to doctors, nurses and other healthcare professionals. Read more

Commenting on the Indian Supreme Courts ruling on Glivec, Stephen Whitehead, Chief Executive of the ABPI said: "We are very disappointed that the Indian Supreme Court has chosen not to grant a patent claim for Glivec despite it being recognised in 40 other countries including China." Read more

Commenting on the Government’s response to the Health Select Committee’s report on the future role of NICE and value-based pricing, Stephen Whitehead, Chief Executive of the ABPI said: “The Government’s wide-ranging response to the Health Select Committee’s report makes a number of important points on the future role of NICE."Read more